Julius Center for Health Sciences and Primary Care, Room Str. 6.131, PO Box 85090, 3508 GA Utrecht, The Netherlands.
Haematologica. 2011 May;96(5):738-43. doi: 10.3324/haematol.2010.029868. Epub 2011 Jan 27.
Severe hemophilia requires life-long treatment with expensive clotting factor concentrates; studies comparing effects of different therapeutic strategies over decades are very difficult to perform. A simulation model was developed to evaluate the long-term outcome of on demand, prophylactic and mixed treatment strategies for patients with severe hemophilia A.
A computer model was developed based on individual patients' data from a Dutch cohort study in which intermediate dose prophylaxis was used and a French cohort study in which on demand treatment was used, and multivariate regression analyses. This model simulated individual patients' life expectancy, onset of bleeding, life-time joint bleeds, radiological outcome and concentrate use according to the different treatment strategies.
According to the model, life-time on demand treatment would result in an average of 1,494 joint bleeds during the hemophiliac's life, and consumption of 4.9 million IU of factor VIII concentrate. In contrast, life-time intermediate dose prophylaxis resulted in a mean of 357 joint bleeds and factor consumption of 8.3 million IU. A multiple switch strategy (between prophylactic and on demand treatment based on bleeding pattern) resulted in a mean number of 395 joint bleeds and factor consumption of 6.6 million IU. The estimated proportion of patients with Pettersson scores over 28 points was 32% for both the prophylactic and the multiple switching strategies, compared to 76% for continuous on demand treatment.
The present model allows evaluation of the impact of various treatment strategies on patients' joint bleeds and clotting factor consumption. It may be expanded with additional data to allow more precise estimates and include economic evaluations of treatment strategies.
重度血友病需要终身使用昂贵的凝血因子浓缩物进行治疗;因此,很难开展长达数十年的不同治疗策略效果的研究。本研究开发了一个模拟模型,用于评估按需治疗、预防性治疗和混合治疗策略对重度血友病 A 患者的长期疗效。
该模型基于荷兰队列研究(使用中等剂量预防治疗)和法国队列研究(使用按需治疗)中患者的个体数据开发,并结合多元回归分析。该模型根据不同的治疗策略,模拟了个体患者的预期寿命、出血发作、终生关节出血、影像学结果和浓缩物使用情况。
根据模型,终生按需治疗将导致患者一生中平均发生 1494 次关节出血,消耗 490 万 IU 的凝血因子 VIII 浓缩物。相比之下,终生中等剂量预防治疗将导致平均发生 357 次关节出血,消耗 830 万 IU 的凝血因子 VIII 浓缩物。基于出血模式的多次切换策略(在预防性和按需治疗之间切换)导致平均发生 395 次关节出血和 660 万 IU 的凝血因子 VIII 消耗。预计预防性和多次切换策略的患者中,Pettersson 评分超过 28 分的比例分别为 32%,而连续按需治疗的这一比例为 76%。
本模型可用于评估各种治疗策略对患者关节出血和凝血因子消耗的影响。该模型可以进一步扩展,纳入更多数据,以便更准确地估计,并纳入治疗策略的经济评估。